(Reuters) -German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals ...

Bayer’s retinal disease treatment Eylea (aflibercept) is set for an extended treatment interval, a label extension that could give the drug an advantage over rival Roche’s Vabysmo (faricimab). A ...

In these open-label extension studies, 24% of nAMD patients and 28% of DME patients who started with Eylea 8 mg at baseline were on six-month treatment intervals by the end of year three. Eylea 8 mg ...

BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...

The FDA approved Eylea for the treatment of retinopathy of prematurity ... Eylea, which is jointly developed by Regeneron and Bayer, is now approved to treat five retinal conditions caused by ...

Bayer BAYRY announced that the Committee ... Aflibercept’s 2 mg solution injection is approved under the brand name Eylea for the treatment of neovascular (wet) age-related macular degeneration ...

Berlin: Bayer has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for Eylea 8 mg (aflibercept 8 mg) for the treatment ...

Eylea, an injection against the leading causes of blindness among the elderly, is currently approved in the EU for treatment intervals of up to five months. Bayer has developed it jointly with ...

If approved, Eylea 8 mg would become the only anti-vascular endothelial growth factor (anti-VEGF) treatment in the EU authorized for six-month intervals for both nAMD and DME, according to Bayer ...